# EDGAR Filing Document

**Accession Number:** 0002108922
**File Stem:** 0001193125-26-036046
**Filing Date:** 2026-2
**Character Count:** 6258
**Document Hash:** 61542d6646e86de7984b16d40d2fe7a2
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-036046.hdr.sgml**: 20260203

**ACCESSION NUMBER**: 0001193125-26-036046

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260126

**FILED AS OF DATE**: 20260203

**DATE AS OF CHANGE**: 20260203

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Williams Sarah Joanne
- **CENTRAL INDEX KEY:** 0002108922

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41331
- **FILM NUMBER:** 26594985

**MAIL ADDRESS:**
- **STREET 1:** C/O AN2 THERAPEUTICS, INC.
- **STREET 2:** 1300 EL CAMINO REAL, SUITE 100
- **CITY:** MENLO PARK
- **STATE:** CA
- **ZIP:** 94025
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** AN2 Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001880438
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 820606654
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 1300 EL CAMINO REAL, SUITE 100
- **CITY:** MENLO PARK
- **STATE:** CA
- **ZIP:** 94025
- **BUSINESS PHONE:** (650) 331-9090

**MAIL ADDRESS:**
- **STREET 1:** 1300 EL CAMINO REAL, SUITE 100
- **CITY:** MENLO PARK
- **STATE:** CA
- **ZIP:** 94025

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Williams Sarah Joanne<br><sub>(Last) (First) (Middle)</sub><br>C/O AN2 THERAPEUTICS, INC.<br>1300 EL CAMINO REAL, SUITE 100<br><sub>(Street)</sub><br>MENLO PARK, CA 94025<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>AN2 Therapeutics, Inc. [ ANTX ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2026-01-26 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [ ] 10% Owner<br>[X] Officer (give title below)   [ ] Other (specify below)<br>_Principal Accounting Officer_ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |
| Common Stock | 18800<sup>(1)</sup> | D |  |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| Stock Option (right to buy) | <sup>(2)</sup> | 2035-02-25 | Common Stock | 21875 | $1.13 | D |  |
| Stock Option (right to buy) | <sup>(3)</sup> | 2034-06-16 | Common Stock | 23700 | $2.07 | D |  |

---

### Footnotes:

(1) Includes the balance of (a) 10,938 RSUs which vest as follows: 1/4th of the RSUs vest in substantially equal installments annually (rounded down to the nearest whole number of shares) over four years from January 1, 2025, and (b) 11,850 RSUs which vest as follows: 1/16th of the RSUs vest in substantially equal installments quarterly (rounded down to the nearest whole number of shares) over four years from May 28, 2024, in each case subject to the Reporting Person continuing to provide services to the Company as an employee, consultant or director of the Company through each applicable vesting date. A total of 3,174 shares from the aggregate number of the RSUs issued under (a) and (b) above were sold to cover taxes and a total of 814 shares were sold on the open market.

(2) The shares subject to the option are exercisable and vest as follows: 1/48th of the shares vest and become exercisable (rounded down to the nearest whole number of shares) monthly over four years from January 1, 2025 until fully vested and exercisable on January 1, 2029, subject to the Reporting Person continuing to provide services to the Company as an employee, consultant or director of the Company through each applicable vesting date.

(3) The shares subject to the option are exercisable and vest as follows: 1/4th of the shares vest and become exercisable (rounded down to the nearest whole number of shares) on the first anniversary of May 28, 2024, and 1/48th of the shares vest and become exercisable monthly (rounded down to the nearest whole number of shares) over the following three years until fully vested and exercisable on May 28, 2028, subject to the Reporting Person continuing to provide services to the Company as an employee, consultant or director of the Company through each applicable vesting date.

**Signature:** /s/ Sarah Joanne Williams  
**Date:** 2026-02-03

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**